Dr João Glasberg speaks to ecancer about METNET which is a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. He initially talks about the background of the study.
The aim of the study was to evaluate the efficacy and safety of metformin monotherapy in patients with advanced/metastatic well-differentiated NET (WD-NET) of gastroenteropancreatic (GEP) or pulmonary origin.
Dr Glasberg then discusses the methodology and key results of the study. The study indicated that metformin monotherapy offers modest antitumour activity in well-differentiated GEP or lung NET.
Dr Glasberg concludes by discussing how these results can impact the future treatment of neuroendocrine tumours.
Read the study here.